CAMBRIDGE, Mass.--(BUSINESS WIRE)--Selventa™, a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, today announced that the Company’s Chief Executive Officer, David de Graaf, has recently been appointed as a Scientific Advisory Board member for the SIB Swiss Institute of Bioinformatics.
